

A randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study)

Bradbury, Charlotte; Fletcher, Kate; Sun, Yongzhong; Heneghan, Carl J.; Gardiner, Chris; Roalfe, Andrea; Hardy, Polly; McCahon, Debbie; Heritage, Gail; Shackelford, Helen; Hobbs, Richard; Fitzmaurice, David

DOI:
[10.1111/bjh.16275](https://doi.org/10.1111/bjh.16275)

License:
Other (please specify with Rights Statement)

Document Version
Peer reviewed version

Citation for published version (Harvard):
Bradbury, C, Fletcher, K, Sun, Y, Heneghan, CJ, Gardiner, C, Roalfe, A, Hardy, P, McCahon, D, Heritage, G, Shackelford, H, Hobbs, R & Fitzmaurice, D 2019, 'A randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study)', *British Journal of Haematology*. <https://doi.org/10.1111/bjh.16275>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

This is the peer reviewed version of the following article: Bradbury, C., Fletcher, K., Sun, Y., Heneghan, C., Gardiner, C., Roalfe, A., Hardy, P., McCahon, D., Heritage, G., Shackelford, H., Hobbs, R. and Fitzmaurice, D. (2019) A randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study), *British Journal of Haematology*, which has been published in final form at <https://doi.org/10.1111/bjh.16275>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 23. Apr. 2024

1 **A Randomised Controlled Trial of Extended Anticoagulation Treatment**
2 **Versus Standard Treatment for the Prevention of Recurrent VTE and Post-**
3 **thrombotic Syndrome in Patients Being Treated for a First Episode of**
4 **Unprovoked VTE (The ExACT Study)**
5

6 Charlotte Bradbury¹

7 Kate Fletcher²

8 Yongzhong Sun²

9 Carl Heneghan³

10 Chris Gardiner⁴

11 Andrea Roalfe³

12 Pollyanna Hardy²

13 Debbie McCahon⁵

14 Gail Heritage²

15 Helen Shackleford²

16 FD Richard Hobbs³

17 David Fitzmaurice⁶

18

19 1. School of Cellular and Molecular Medicine, University of Bristol

20 2. Institute of Applied Health Research, The University of Birmingham

21 3. Nuffield Department of Primary Care Health Sciences, Medical Sciences Division, University
22 of Oxford

23 4. Haemostasis Research Unit (HRU), Department of Haematology, University College London

24 5. Centre for Academic Primary Care, Bristol Medical School, University of Bristol

25 6. Unit of Academic Primary Care, Warwick Medical School, University of Warwick

26

27

28

1 **Summary**

2

3 Venous thromboembolism (VTE) is prevalent and impactful, with a risk of death, morbidity
4 and recurrence. Post thrombotic syndrome (PTS) is a common consequence and associated
5 with impaired quality of life (QoL).

6

7 The ExACT study was a non-blinded, prospective, multi-centred RCT comparing extended
8 versus limited duration anticoagulation following a first unprovoked VTE (Proximal DVT or
9 PE). Adults were eligible if they had completed ≥ 3 months anticoagulation (remaining
10 anticoagulated). The primary outcome was time to first recurrent VTE from randomisation.
11 The secondary outcomes included PTS severity, bleeding, QoL and D-dimers.

12

13 281 patients were recruited, randomised and followed up for 24 months (mean age 63,
14 Male:Female 2:1). There was a significant reduction in recurrent VTE for patients receiving
15 extended anticoagulation (2.75 vs 13.54 events/100 patient years, aHR 0.20(95%CI:0.09 to
16 0.46, $p < 0.001$)) with a non-significant increase in major bleeding (3.54 vs 1.18 events/100
17 patient years, aHR 2.99(95%CI:0.81 to 11.05, $p = 0.10$)). PTS and QoL outcomes were no
18 different between groups. D-dimer results (on anticoagulation) did not predict VTE
19 recurrence.

20

21 In conclusion, extended anticoagulation reduced VTE recurrence but did not reduce PTS or
22 improve QoL and was associated with a non-significant increase in bleeding. Results also
23 suggest very limited clinical utility of D-dimer testing on anticoagulated patients.

24

25 **Key words**

26 Thrombosis (venous), Anticoagulation, Warfarin, Post Thrombotic Syndrome, D-dimer

27

28

1 **Introduction**

2 VTE is a prevalent and severe disease with a risk of death, recurrence, psychological impact,
3 and long-term morbidity resulting from PTS with impaired QoL (Martinez *et al* 2014, Cohen
4 *et al* 2007, Noble *et al* 2014, Kahn *et al* 2008, 2016).

5
6 Anticoagulation therapy (AT) remains the mainstay of treatment for VTE. Clinical guidelines
7 recommend a minimum of 3 months AT for proximal DVT or PE, with consideration of long-
8 term, indefinite duration AT following an unprovoked VTE due to the higher risk of VTE
9 recurrence than following a provoked VTE (Martinez *et al* 2014, Baglin *et al* 2003, NICE
10 CG144, Kearon *et al* 2016, Keeling *et al* 2011). Guidelines also recommend weighing up
11 individual additional risk factors for recurrence and bleeding with consideration of patient
12 preference to inform anticoagulation duration decisions. A further consideration is the
13 potential consequence of recurrence, with a higher risk of death with symptomatic PE than
14 DVT (Douketis *et al* 2007) and recurrence as PE more likely if initial presentation was PE
15 (Baglin *et al* 2010). Other factors associated with an increased VTE recurrence risk include
16 male sex (Roach *et al* 2015), raised D-dimer after cessation of anticoagulation for 1 month
17 (Palareti *et al* 2002, Verhovsek *et al* 2008) and PTS (Rodger *et al* 2008). Various scores exist
18 to aid recurrence risk stratification and counselling of individual patients (e.g. DASH, Tosetto
19 *et al* 2012) but anticoagulation duration decisions are sometimes challenging.

20
21 PTS affects up to 50% of patients following DVT (Kahn *et al* 2016) and is associated with
22 significant morbidity and negative impact on QoL. PTS manifests as a spectrum of symptoms
23 and signs of chronic venous insufficiency in the lower limb including chronic, persistent pain,
24 swelling, skin changes and leg ulcers. PTS is burdensome and costly due to its prevalence,
25 severity, and chronicity. At the current time, management remains unsatisfactory and there
26 is no cure for PTS. In addition, there are no known effective strategies to prevent PTS
27 following a DVT. Known risk factors for development of PTS include age >65 years, ipsilateral
28 DVT recurrence and subtherapeutic INR results if on warfarin (>50% of time with
29 INR<2.0)(Van Dongen *et al* 2005). Therefore, it is possible that extended duration AT may
30 reduce risk of PTS by reducing risk of ipsilateral DVT recurrence (including subclinical
31 recurrence) that may further damage the vascular pump. The 10-year follow-up of the
32 DURAC 1 study with 545 evaluable patients showed no effect of initial anticoagulation

1 duration (6 weeks versus 6 months) on risk for PTS in multivariate analysis (Schulman *et al*
2 2006). However, there has been no previous studies to test whether extended
3 anticoagulation duration (beyond 6m) can reduce the risk of PTS.

4
5 The ExACT study was designed to answer whether extended AT for unprovoked VTE,
6 reduces VTE recurrence and/or the incidence and severity of PTS compared to limited AT. It
7 also assesses whether extended AT is associated with increased bleeding and improved QoL.
8 The relationship between VTE recurrence and baseline D-dimer results (all participants
9 whilst still anticoagulated), and between VTE recurrence and Therapeutic Time in Range
10 (TTR) for the extended AT group was also explored.

11

12 **Methods**

13 *Trial design and participants*

14 ExACT was a non-blinded, multi-centre, two-arm, parallel-group RCT. Eligible patients were
15 aged ≥ 18 years with a first unprovoked proximal DVT or PE who had completed a minimum
16 of 3 months AT (target INR 2-3 for those taking warfarin) and remained anticoagulated.
17 Patients were excluded if they had another indication for long-term AT (e.g. AF), were at
18 high risk of bleeding (e.g. additional antiplatelet) or very high risk of VTE recurrence (e.g.
19 active cancer or antiphospholipid syndrome) or a life expectancy < 5 years. The full list of
20 exclusion criteria is available in the protocol (Tullett *et al* 2013).

21

22 Trial oversight was by a Trial Steering Committee (TSC) and an independent Data Monitoring
23 Committee (IDMC). Ethics permission was granted by Trent Research Ethics Committee;
24 reference 11/H0605/5. The trial is registered (ISRCTN:73819751 and EUDRACT:2101-
25 022119-20).

26

27 *Recruitment, randomisation and intervention*

28 Patients were identified from UK NHS anticoagulant clinics. Patients who gave informed,
29 written consent were randomised (1:1) to either extended AT for 24 months or discontinued

1 AT. Randomisation was performed within the web-based computerised clinical case report
2 form. The software used random blocks randomisation (block size of 4) stratified by
3 diagnosis (DVT or PE). All participants were asked to attend 6 monthly study follow-up clinic
4 appointments for two years (5 visits in total).

5

6 *Blood samples*

7 D-dimers were tested at the baseline appointment (on anticoagulation) on Point of Care
8 (POC) device (Cobas h 232, Roche Diagnostics). Patient and researcher were blinded to
9 these results.

10

11 *Outcomes*

12 The primary outcome was the time to first recurrent venous thromboembolism (VTE)
13 between randomisation and 24 months. The secondary outcomes were: measures of
14 incidence and severity of PTS using the Villalta Scale applied to both legs at baseline and 6
15 monthly follow-up clinic appointments (Kahn *et al* 2009), bleeding events (major and
16 clinically relevant non-major, CRNM) and QoL (VEINES-QOL (22) and EQ-5D-3L)(Khan *et al*
17 2006) at 6 monthly follow-up clinic appointments.

18

19 The relationship between VTE recurrence and baseline D-dimer results for all participants,
20 and between VTE recurrence and Therapeutic Time in Range (TTR) for the extended AT
21 group was also explored.

22

23 An Independent Adjudication Committee, blind to the intervention allocation, scrutinised all
24 thrombotic and haemorrhagic events in order to obtain objective confirmation.

25

26 *Statistical analysis*

27 *Sample Size:*

1 The study was designed to compare 2-year VTE recurrence rates between participants in the
2 extended versus discontinued AT arms, and also to compare these rates for a group of
3 participants with a baseline raised D-dimer (Palareti *et al* 2002). A sample size of 352 (176
4 per arm) would be sufficient to detect a clinically important difference between the arms
5 with minimum 86% power, two-sided alpha=0.05, assuming recurrence rates between 1.4%
6 and 4.3% for the extended AT arm and 14.2% in the discontinued AT arm (Prandoni *et al*
7 2007). Recruitment was lower than expected and at the TSC request, the power calculation
8 was re-estimated where it was determined that a sample of 270 participants (allowing for
9 10% loss to follow up) would provide at least 80% power to detect the planned effect sizes.

10

11 *Analysis*

12 All primary analyses (primary and secondary outcomes) were performed on an intention to
13 treat basis (ITT).

14

15 Participant characteristics are summarised by treatment arm using descriptive statistics.

16

17 The number and percentage of participants with at least one recurrent VTE is presented by
18 trial arm. Cox regression analysis was used to compare the time to first recurrent VTE
19 between randomisation arms, censoring for deaths, losses to follow-up and withdrawals of
20 consent to use data. The analysis was adjusted for diagnosis (DVT/PE) at baseline. The
21 proportional hazards assumption was tested by cumulative log hazard plots and including a
22 time by treatment covariate in the analysis. The treatment effect is presented as a hazard
23 ratio, with the total number of events and the number of events per 100 patient years to aid
24 interpretation of the data.

25

26 Analysis to compare the time to the first major and CRNM bleeding events (as separate
27 outcomes) between randomisation arms was performed as per the primary outcome.

28

29 Repeated measures mixed modelling was used to compare the PTS score between arms
30 over the 2 year follow up. The analysis allowed for the repeated nature of the data

1 measured at 6, 12, 18 and 24 months, including an interaction term between treatment and
2 time point. The worst score from both of the participant's legs was counted as the score for
3 the participant. The model was adjusted for the baseline PTS score; assessment time and
4 diagnosis (DVT/PE) at baseline were included as fixed effects. Model assumptions were
5 checked for evidence of non-normality in the residuals. The adjusted mean PTS scores at
6 each time point are presented by arm. The presence and severity of PTS is also reported,
7 using frequencies and percentages, according to the following cut offs (0-4:no PTS, 5-9:mild
8 PTS, 10-14:moderate PTS, ≥ 15 :severe PTS).

9

10 Estimates of treatment effects are presented with 95%, two-sided confidence intervals and
11 P values.

12

13 Subgroup analyses were limited to primary outcome (time to first VTE recurrence) and main
14 secondary outcome (time to first major bleeding event) and the predefined subgroups sex
15 and age (≤ 65 , >65 years). Each subgroup effect was independently assessed by the inclusion
16 of a treatment arm by subgroup interaction term in the Cox model. Subgroup related
17 estimates and 95% confidence intervals are presented with interaction results alongside.

18

19 VTE recurrence rates are summarised by baseline D-Dimer level ($<0.5\mu\text{g/ml}$ and $\geq 0.5\mu\text{g/ml}$)
20 for all participants. TTR results are summarised for participants on warfarin in the extended
21 AT group by whether or not a VTE recurrence occurred during follow-up.

22

23 Stata version 12 was used for all analyses.

24

25 **Results**

26

27 *Participant recruitment*

1 **Figures 1A and 1B** summarise the flow of patients from initial screening through
2 recruitment, randomisation and follow up. Two hundred and eighty-one patients provided
3 written informed consent to participate and were randomised between July 2011 and
4 February 2015 (141 to the extended AT and 140 to discontinued AT). In the extended AT
5 arm, only 2 patients continued on rivaroxaban and the others (n=139) remained on
6 warfarin. All 281 trial participants attended visit 1, 273/281 (97%) attended visit 2, 263
7 (94%) attended visit 3 and 260/281 (93%) visit 4.

8
9 Six participants in the discontinued AT group (4 withdrawals, 1 protein S deficiency and 1
10 antithrombin deficiency) and two in the extended AT group (1 withdrawal and 1
11 antiphospholipid syndrome) were excluded from the final ITT analysis by post-
12 randomisation pre-defined exclusions.

13 14 *Baseline Characteristics*

15 No differences were found in baseline characteristics (**Table 1**). The mean age of
16 participants was 63, with a roughly even split between DVT and PE, whilst 67% of
17 participants were male.

18 *Primary outcome*

19 Over 24 months follow up, there were 32 recurrent VTEs in 31 patients (13.54 events/100
20 patient years, PY) within the discontinued AT group versus 7 events in 7 patients (2.75
21 events/100PY) in the extended AT group (aHR=0.20, 95% CI: 0.09 to 0.46, p<0.001)(**Table 2A,**
22 **Figure 2A**). There was no evidence that sex or age group had a differential effect on the risk
23 of VTE recurrence (p=0.099 and p=0.267 respectively **Table 2B**).

24 *Secondary outcomes*

25 There were 3 major bleeding events (1.18/100PY) in the discontinued AT group versus 9
26 (3.54/100PY) in the extended anticoagulation group (aHR=2.99, 95%CI: 0.81 to 11.05,
27 p=0.10). There were 19 clinically relevant non-major bleeding (CRNM) events (8.13/100PY)
28 in the discontinued AT group, and 28(12.50/100PY) in the extended AT group
29 (aHR=1.51, 95%CI: 0.84 to 2.71, p=0.165). These differences were not statistically significant
30 (**Table 2A, Figure 2B and C**). There was no evidence that sex or age group had a differential
31 effect on the risk of major bleeding (p=0.96 and p=0.19 resp.) (**Table 2B**).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

D-dimers were tested at baseline in 273 patients and only 12 patients (4.4%) had D Dimer \geq 0.5 μ g/ml and of these, 3 patients had recurrent VTE and 9 did not. A higher percentage of those with VTE recurrence had a baseline D-dimer \geq 0.5 μ g/ml (n=3 of 38, 7.89% vs n=9 of 235, 3.83%) but this was not statistically significant (**Table 3A**).

Similarly, time in therapeutic range (TTR) for patients on extended AT with warfarin was not significantly different between those with or without recurrence but the number of recurrences were small (**Table 3B**). Patients randomised to warfarin overall had a mean time in therapeutic range (TTR) of 77% (recurrent VTE TTR=84% vs no recurrence=76%).

Outcome measures of QoL and PTS were not different between the groups (**Table 4A**). An additional post-hoc analysis of patients only presenting with DVT at baseline, also showed no evidence of a difference in PTS outcomes with extended or discontinued AT (**Table 4B**).

Discussion

The ExACT study adds to accumulating evidence that extended AT reduces risk of VTE recurrence in patients with a first unprovoked VTE but also adds new perspective by assessing the additional clinically relevant outcomes of PTS and QoL. ExACT also explores the value of D-dimer testing on anticoagulated patients to predict VTE recurrence.

A recent Health Technology Assessment (Sterne *et al* 2017) reviewed all RCTs for VTE secondary prevention and found 10 multicentre phase III trials (total n=10,390 participants). Four studies evaluated therapeutic warfarin for varying durations beyond 3 months versus no anticoagulation (Campbell *et al* 2007, Agnelli *et al* 2001, Agnelli *et al* 2003, Kearon *et al* 1999), two evaluated aspirin (Beccattini *et al* 2012, Brighton *et al* 2012) and four evaluated direct oral anticoagulants (DOACs) (Agnelli *et al* 2013, Wells *et al* 2016, Romualdi *et al* 2011, Bauersachs *et al* 2010, Schulman *et al* 2013, Weitz *et al* 2017). All currently licensed DOACs for this indication (Apixaban, Rivaroxaban and Dabigatran) have been compared to placebo. Rivaroxaban has also been compared to aspirin and Dabigatran has also been compared to

1 warfarin. In addition, Rivaroxaban and Apixaban have been tested at lower “prophylactic
2 doses” for VTE secondary prevention.

3

4 Taken together, the published evidence demonstrates that extended AT (warfarin or DOAC)
5 beyond 3 months significantly reduces VTE recurrence but only whilst on anticoagulation
6 and balanced against this is an increased risk of bleeding. Compared to Warfarin, Dabigatran
7 was non-inferior in efficacy but with less major or CRNM bleeding events in the dabigatran
8 arm. Compared to placebo, Dabigatran, Rivaroxaban and Apixaban all reduced the risk of
9 VTE recurrence but resulted in increased bleeding, apart from the lower dose of apixaban
10 2.5mg bd which had equivalent bleeding risk to placebo. Compared to aspirin, rivaroxaban
11 was more effective with equivalent bleeding risk.

12

13 The ExACT study is in alignment with this literature, demonstrating an 80% reduction in VTE
14 recurrence risk for patients receiving extended AT following an unprovoked VTE. There were
15 numerically more bleeding events in the extended AT arm, but not a statistically significant
16 difference, likely due to the small number of events. Interpretation of subgroup analyses in
17 the ExACT trial (age and sex) is also limited due to insufficient patient numbers (including
18 only 1/3 female) and infrequent events. For example, the 3 fold increase in major bleeding
19 events in >65 years patients on extended AT aligns with previous literature, but the small
20 number of events meant statistical significance was not reached.

21

22 The TTR for the ExACT study was 77% which compares favourably with warfarin secondary
23 prevention clinical trials (mean TTR: 64% in LAFIT, 65.3% in RE-MEDY and 81% in WODIT-
24 DVT). Subtherapeutic INR has been associated with risk of VTE recurrence in previous
25 studies (Nordstrom et al 2015) but in ExACT, the few recurrences that occurred on extended
26 AT did not appear related to poor INR control (mean TTR=84% in those with VTE recurrence
27 vs 76%).

28

29 Remarkably, none of the published 10 RCTs for VTE secondary prevention have included
30 measurement of PTS as an outcome and as this is the greatest source of morbidity and
31 impaired quality of life following a DVT, the inclusion of this assessment in the ExACT study
32 is important and novel. Currently, there are no effective PTS prevention interventions that

1 are broadly applicable to patients following a DVT. Although the CaVenT RCT demonstrated
2 a reduced risk of PTS with catheter directed thrombolysis for proximal DVT (Haig et al 2016),
3 the ATTRACT study failed to demonstrate benefit (Vedantham 2017). In addition, the
4 consistently reported increased bleeding risk and need for interventional radiology makes
5 this intervention only applicable to a minority of patients. Compression stockings were long
6 thought to reduce risk of PTS following DVT and were routinely used. However, recent data
7 including large placebo controlled RCT have failed to demonstrate benefit of compression
8 stockings to reduce risk of PTS following DVT (Subbiah *et al* 2016).

9

10 The ExACT study is the first to evaluate whether extended AT could reduce the incidence of
11 PTS. It has previously been reported that the majority of patients with a PE diagnosis have
12 an associated DVT (approximately 70%, Wilbur and Shian 2017), but it is not standard
13 practice to screen and diagnose these as it does not influence management. Consistent with
14 this, patients recruited to the ExACT study with a PE were not routinely screened for DVT
15 but PTS assessments were done for all patients (DVT and PE). By 2 years follow up, although
16 over half of patients had developed some degree of PTS, only a minority of these were
17 severe and there were no differences in frequency or severity between those patients
18 randomised to extended versus discontinued AT. A post-hoc restricted analysis of patients
19 only presenting with DVT also showed no evidence of a difference in PTS outcomes between
20 groups. Previous data demonstrated that subtherapeutic INRs in the initial phase of AT is a
21 risk factor for PTS (van Dongen *et al* 2005), which when combined with ExACT results,
22 suggests optimising initial anticoagulation treatment is the priority to reduce PTS risk rather
23 than extending the duration. It also suggests that the pathogenesis of PTS results from
24 venous damage associated with the initial acute event rather than any ongoing further new
25 thrombotic process. In addition, extending AT did not show evidence of an improved QoL as
26 assessed by either generic or disease specific measures of QoL.

27

28 To-date, numerous clinical studies have evaluated D-dimer assays as a predictive biomarker
29 for VTE recurrence but most studies have tested D-dimers after discontinuation of
30 anticoagulation for 1 month. Raised D-dimers at this time point have been associated with a
31 higher risk of VTE recurrence (Verhovsek *et al* 2008, Palareti *et al* 2002). However, stopping

1 anticoagulation for 1 month to enable testing is logistically complex and potentially harmful
2 with risk of VTE recurrence while awaiting testing.

3

4 Kearon et al assessed D-dimer testing to select patients with a first unprovoked venous
5 thromboembolism who can stop anticoagulant therapy in a cohort study (n=410). By far the
6 majority (97%) of anticoagulated patients had a negative D-dimer. Of these, 85% continued
7 to have negative D Dimers after stopping anticoagulation for 1 month but still remained at
8 high risk of recurrent VTE (annual recurrence of 9.7% men and 5.4% women)(Kearon *et al*
9 2015). This highlights the reduced sensitivity of D-dimer testing in anticoagulated patients
10 and the limitations of D-dimer testing to decide which patients can safely stop
11 anticoagulation. Kearon et al have recently published an updated analysis of this cohort with
12 extended follow up (median of 5 years) and demonstrated a continued high risk of VTE
13 recurrence in male patients with a negative D-dimer (testing off anticoagulation,
14 7.5%/PY)(Kearon *et al* 2019). Similarly, in the ExACT study, only a small proportion (4.4%) of
15 participants had positive D-dimers whilst on anticoagulation. Out of the 38 participants who
16 went on to develop VTE recurrences, by far the majority (n=33, 87%) had negative D-dimer
17 results. Therefore, D-dimer results, **using a standard cut off**, on anticoagulated patients are
18 not helpful to determine patients at low risk of VTE recurrence to stop anticoagulation. **It is**
19 **possible that a lower D-dimer cut off threshold could be more informative for patients on**
20 **anticoagulation. The HERDOO2 rule has been prospectively validated using a lower cut off**
21 **(250mcg/L) and a different D-dimer assay (VIDAS)(Roger et al 2017). However, other**
22 **investigators have not used this cut off (e.g. Palareti et al Blood 2014, Kearon C 2015 and**
23 **2019). The optimal D-dimer cut off and specific assay to use in this context remains**
24 **uncertain. In addition, it is unclear whether single testing or serial testing is better and how**
25 **results should influence clinical management (Kearon and Akl 2014).**

26

27 The limitations of the ExACT study include that nearly all patients in the extended AT arm
28 received warfarin treatment whereas DOACs are now the preferred choice for VTE
29 secondary prevention in the majority of patients. **In addition, interpretation of bleeding**

1 outcomes and subgroup analyses (age and sex) are limited due to insufficient patient
2 numbers and infrequent events.

3
4 In summary, the ExACT study confirms that extended AT treatment for a first unprovoked
5 VTE provides substantial protection in terms of recurrent VTE but does not reduce risk of
6 PTS or improve QoL and is associated with a non-significant increase in bleeding. Finally, D-
7 dimer results, using a standard cut off, in anticoagulated patients are unlikely to inform
8 clinical decisions.

9 10 **Funding**

11 This manuscript has been prepared as part of work package funded by the National Institute
12 for Health Research (NIHR) under its Programme Grants for Applied Research programme
13 (RP-PG-0608-10073). The views expressed in this paper are those of the authors and not
14 necessarily those of the NHS, the NIHR or the Department of Health.

15 16 **Author Contributions**

17 The study was designed, and funding were secured by DF, FDRH, CG, CH, and SJ. KF and DM
18 undertook day-to-day management of the study and were responsible for data
19 management and quality assurance. HS and GH undertook data collection. AR and PH
20 provided senior quantitative methodological support for the design of the statistical
21 analysis. AR and YS developed the statistical analysis plan, YS undertook the statistical
22 analysis and contributed to the interpretation of findings. DM and KF contributed to the
23 descriptive analysis. All authors contributed to data interpretation. CB and DF wrote the first
24 draft of this paper and all authors were responsible for subsequent critical revision of the
25 manuscript.

26 27 **Declaration of interests**

28 CB has received speaker fees from BMS Pfizer, Novartis and Janssen. Advisory fees: Ablynx
29 and Novartis. Funding to attend conferences: Amgen and Bayer. FDRH has received
30 occasional consultancy fees and expenses from BMS/Pfizer and Boehringer Ingelheim. None
31 of the other authors have competing interests to declare.

1

2 **Acknowledgements**

3 The authors acknowledge with thanks, Roger Holder (retired) for his contribution to the
4 design and protocol development and Linda Nichols for statistical support to the Data
5 Monitoring Committee. FDRH acknowledges his part funding from the NIHR School for
6 Primary Care Research, the NIHR Collaboration for Leadership in Health Research and Care
7 (CLARHC) Oxford, the NIHR Oxford Biomedical Research Centre (BRC) and the NIHR Oxford
8 Medtrch and in-vitro Diagnostics Co-operative (MIC). AR acknowledges support from the
9 NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation
10 Trust.

11

1 **References**

2 Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous
3 thromboembolism. *The New England journal of medicine*. 2013; 368(8): 699-708.

4

5 Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first
6 episode of pulmonary embolism. *Annals of internal medicine*. 2003; 139(1): 19-25.

7

8 Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral
9 anticoagulant therapy for idiopathic deep venous thrombosis. *Warfarin Optimal Duration*
10 *Italian Trial Investigators. The New England journal of medicine*. 2001; 345(3): 165-9.

11

12 Baglin T, Douketis J, Tosetto A, et al. Does the clinical presentation and extent of venous
13 thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. *Journal*
14 *of thrombosis and haemostasis*. 2010; 8(11): 2436-42.

15

16 Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism
17 in relation to clinical and thrombophilic risk factors: prospective cohort study. *Lancet*. 2003;
18 362(9383): 523-6.

19

20 Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous
21 thromboembolism. *The New England journal of medicine*. 2010; 363(26): 2499-510.

22

23 Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous
24 thromboembolism. *The New England journal of medicine*. 2012; 366(21): 1959-67.

25

26 Bell EJ, Lutsey PL, Basu S, et al. Lifetime Risk of Venous Thromboembolism in Two Cohort
27 Studies. *The American journal of medicine*. 2016; 129(3): 339.e19-26.

28

29 Broderick C, Armon MP, Watson L. Thrombolysis for acute deep vein thrombosis. *Cochrane*
30 *Database Syst Rev*. 2016 Nov; 2016(11): CD002783.

31

1 Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous
2 thromboembolism. *The New England journal of medicine* 2012; 367(21): 1979-87.
3
4 Campbell IA, Bentley DP, Prescott RJ, et al. Anticoagulation for three versus six months in
5 patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. *BMJ*.
6 2007; 334(7595): 674.
7
8 Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The
9 number of VTE events and associated morbidity and mortality. *Thrombosis and*
10 *haemostasis*. 2007; 98(4): 756-64.
11
12 Chiasakul T, Cuker A. The case for catheter-directed thrombolysis in selected patients with
13 acute proximal deep vein thrombosis. *Blood advances*. 2018; 2(14): 1799-802.
14
15 Douketis JD, Gu CS, Schulman S, et al. The risk for fatal pulmonary embolism after
16 discontinuing anticoagulant therapy for venous thromboembolism. *Annals of internal*
17 *medicine* 2007; 147(11): 766-74.
18
19 Haig Y, Enden T, Grotta O, et al. Post-thrombotic syndrome after catheter-directed
20 thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label,
21 randomised controlled trial. *The Lancet Haematology*. 2016; 3(2): e64-71.
22
23 Kahn SR. The post-thrombotic syndrome. *American Society of Hematology Education*
24 *Program*. 2016; 2016(1): 413-8.
25
26 Kahn SR. Measurement properties of the Villalta scale to define and classify the severity of
27 the post-thrombotic syndrome. *Journal of thrombosis and haemostasis*. 2009; 7(5): 884-8.
28
29 Kahn SR, Lamping DL, Ducruet T, et al. VEINES-QOL/Sym questionnaire was a reliable and
30 valid disease-specific quality of life measure for deep venous thrombosis. *Journal of clinical*
31 *epidemiology*. 2006; 59(10): 1049-56.

1 Kahn SR, Shbaklo H, Lamping DL, et al. Determinants of health-related quality of life during
2 the 2 years following deep vein thrombosis. *Journal of thrombosis and haemostasis*. 2008;
3 6(7): 1105-12.
4
5 **Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and**
6 **pulmonary embolism. *Blood*. 2014 Mar 20;123(12):1794-801.**
7
8 Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline
9 and Expert Panel Report. *Chest*. 2016; 149(2): 315-52.
10
11 Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with
12 extended anticoagulation for a first episode of idiopathic venous thromboembolism. *The*
13 *New England journal of medicine*. 1999; 340(12): 901-7.
14
15 Kearon C, Parpia S, Spencer FA, et al. Long term risk of recurrence in patients with a first
16 unprovoked venous thromboembolism managed according to D-dimer results; a cohort
17 study. *Journal of thrombosis and haemostasis* 2019. Doi:10.1111/jth.14458
18
19 Kearon C, Spencer FA, O'Keefe D, et al. D-dimer testing to select patients with a first
20 unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.
21 *Annals of internal medicine*. 2015; 162(1): 27-34.
22
23 Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin - fourth
24 edition. *British journal of haematology*. 2011; 154(3): 311-24.
25
26 Martinez C, Cohen AT, Bamber L, Rietbrock S. Epidemiology of first and recurrent venous
27 thromboembolism: a population-based cohort study in patients without active cancer.
28 *Thrombosis and haemostasis*. 2014; 112(2): 255-63.
29
30 McNeil K, Dunning J. Chronic thromboembolic pulmonary hypertension (CTEPH). *Heart*.
31 2007; 93(9): 1152-8.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

NICE CG 144: Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. June 2012. Available at <https://www.nice.org.uk/Guidance/cg144> (Accessed March 2019)

Noble S, Lewis R, Whithers J, Lewis S, Bennett P. Long-term psychological consequences of symptomatic pulmonary embolism: a qualitative study. *BMJ open*. 2014; 4(4): e004561.

Nordstrom BL, Evans MA, Murphy BR, et al. Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin. *Current medical research and opinion*. 2015; 31(3): 439-47.

Palareti G, Legani C, Cosmi B et al. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. *Thromb Haemost*. 2002; 87(1):7-12.

Palareti G, Cosmi B, Legnani C. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. *Blood*. 2014 Jul 10;124(2):196-203.

Poston JN, Garcia DA. The case against catheter-directed thrombolysis in patients with proximal deep vein thrombosis. *Blood advances*. 2018; 2(14): 1803-5.

Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. *Haematologica*. 2007;92(2):199–205

Roach RE, Lijfering WM, Tait RC, et al. Sex difference in the risk of recurrent venous thrombosis: a detailed analysis in four European cohorts. *Journal of thrombosis and haemostasis*. 2015; 13(10): 1815-22.

1 Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at
2 low risk for recurrence who can discontinue anticoagulant therapy. CMAJ: Canadian Medical
3 Association journal = journal de l'Association medicale Canadienne. 2008; 179(5): 417-26.
4

5 Rodger MA, Le Gal G, Anderson DR et al. Validating the HERDOO2 rule to guide treatment
6 duration for women with unprovoked venous thrombosis: multinational prospective cohort
7 management study. BMJ. 2017 Mar 17;356: j1065. doi: 10.1136/bmj.j1065.
8

9 Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous
10 thromboembolism: the continued treatment study (EINSTEIN-extension study). Expert
11 review of cardiovascular therapy. 2011; 9(7): 841-4.
12

13 Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in
14 venous thromboembolism. The New England journal of medicine. 2013; 368(8): 709-18.
15

16 Schulman S, Lindmarker P, Holmström M, et al. Post-thrombotic syndrome, recurrence, and
17 death 10 years after the first episode of venous thromboembolism treated with warfarin for
18 6 weeks or 6 months. J Thromb Haemost. 2006 Apr;4(4):734-42.
19

20 Sterne JA, Bodalia PN, Bryden PA, et al. Oral anticoagulants for primary prevention,
21 treatment and secondary prevention of venous thromboembolic disease, and for prevention
22 of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-
23 effectiveness analysis. Health technology assessment (Winchester, England) 2017; 21(9): 1-
24 386.
25

26 Subbiah R, Aggarwal V, Zhao H, et al. Effect of compression stockings on post thrombotic
27 syndrome in patients with deep vein thrombosis: a meta-analysis of randomised controlled
28 trials. The Lancet Haematology. 2016; 3(6): e293-300.
29

30 Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous
31 unprovoked venous thromboembolism: a proposed prediction score (DASH). Journal of
32 thrombosis and haemostasis. 2012; 10(6): 1019-25.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Tullett J, Murray E, Nichols L, et al. Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study). *BMC cardiovascular disorders* 2013; 13: 16.

van Dongen CJ, Prandoni P, Frulla M, et al. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. *Journal of thrombosis and haemostasis*. 2005; 3(5): 939-42.

Vedantham S, Goldhaber SZ, Julian JA, et al, for the ATTRACT Trial Investigators Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. *N Engl J Med*. 2017 Dec 7; 377(23): 2240–2252.

Verhovsek M, Douketis JD, Yi Q, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. *Annals of internal medicine*. 2008; 149(7): 481-90, w94.

Wells PS, Prins MH, Levitan B, et al. Long-term Anticoagulation with Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension. *Chest*. 2016; 150(5): 1059

Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. *The New England journal of medicine*. 2017; 376(13): 1211-22.

Wilbur J and Shian B. Deep Venous Thrombosis and Pulmonary Embolism: Current Therapy. *Am Fam Physician*. 2017; 95(5):295-302.